Nebulized Therapies in COPD: Past, Present, and the Future

References

• Centers for Disease Control and Prevention. COPD. Available from: https://www.cdc.gov/dotw/copd/index.html. Accessed 522, 2020.
   Google Scholar
• Centers for Disease Control and Prevention. National vital statistics reports. Final data for 2017. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_09-508.pdf. Accessed 512, 2020.
   Google Scholar
• COPD predicted to be third leading cause of death in 2030. World health stat; 2008 Available from: https://www.who.int/respiratory/copd/World_Health_Statistics_2008/en/. Accessed 512, 2020.
   Google Scholar
• American Lung Association. How serious is COPD; 2019 Available from: https://www.lung.org/lung-health-and-diseases/lung-disease-lookup/copd/learn-about-copd/how-serious-is-copd.html. Accessed 512, 2020.
   Google Scholar
• MathersC, LoncarD. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. doi:10.1371/journal.pmed.003044217132052
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease; 2020 Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-POCKET-GUIDE-FINAL-pgsized-wms.pdf. Accessed 310, 2020.
   Google Scholar
• BorghardtJ, KloftC, SharmaA. Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes. Can Respir J. 2018;2018:2732017. doi:10.1155/2018/273201730018677
   PubMed Web of Science ®Google Scholar
• TashkinDP. A review of nebulized drug delivery in COPD. Int J Chron Obstruct Pulmon Dis. 2016;18(11):2585–2596. doi:10.2147/COPD.S114034
   Web of Science ®Google Scholar
• Lonhala® Magnair® (glycopyrrolate) inhalation solution [highlights of prescribing information]. Marlborough, MA: Sunovion Respiratory Development Inc; 2019 Available from: https://www.lonhalamagnair.com/LonhalaMagnair-Prescribing-Information.pdf. Accessed 625, 2020.
   Google Scholar
• YUPELRI® (revefenacin) inhalation solution [highlights of prescribing information]. Morgantown, WV: Mylan Specialty L.P; 2019 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210598s001lbl.pdf. Accessed 310, 2020..
   Google Scholar
• FranciosiL, DiamantZ, BannerK, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med. 2013;1:714–727. doi:10.1016/S2213-2600(13)70187-524429275
   PubMed Web of Science ®Google Scholar
• MartinC, FrijaJ, BurgelP. Dysfunctional lung anatomy and small airways degeneration in COPD. Int J Chron Obstruct Pulmon Dis. 2013;8:7–13. doi:10.2147/COPD.S2829023319856
   PubMed Web of Science ®Google Scholar
• LabirisN, DolovichM. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):600–612. doi:10.1046/j.1365-2125.2003.01893.x14616419
   PubMed Web of Science ®Google Scholar
• LabirisN, DolovichM. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):588–599. doi:10.1046/j.1365-2125.2003.01892.x14616418
   PubMed Web of Science ®Google Scholar
• PleasantsR, HessD. Aerosol delivery devices for obstructive lung diseases. Respir Care. 2018;63(6):708–733. doi:10.4187/respcare.0629029794206
   PubMed Web of Science ®Google Scholar
• NaharK, GuptaN, GauvinR, et al. In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals. Eur J Pharm Sci. 2013;49(5):805–818. doi:10.1016/j.ejps.2013.06.00423797056
   PubMed Web of Science ®Google Scholar
• TelkoM, HickeyA. Dry powder inhaler formulation. Respir Care. 2005;50(9):1209–1227.16122404
   PubMedGoogle Scholar
• UsmaniO, BiddiscombeM, BarnesP. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med. 2005;172(12):1497–1504. doi:10.1164/rccm.200410-1414OC16192448
   PubMed Web of Science ®Google Scholar
• LaubeB, JanssensH, de JonghF, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37(6):1308–1331. doi:10.1183/09031936.0016641021310878
   PubMed Web of Science ®Google Scholar
• DolovichM. Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Respir Care. 2000;45(6):597–608.10894453
   PubMedGoogle Scholar
• TaffetG, DonohueJ, AltmanP. Considerations for managing chronic obstructive pulmonary disease in the elderly. Clin Interv Aging. 2014;9:23–30. doi:10.2147/CIA.S5299924376347
   PubMed Web of Science ®Google Scholar
• YawnB, ColiceG, HodderR. Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care setting. Int J Chron Obstruct Pulmon Dis. 2012;7:495–502. doi:10.2147/COPD.S3267422888221
   PubMed Web of Science ®Google Scholar
• GhoshS, OharJ, DrummondM. Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2017;30(6):381–387. doi:10.1089/jamp.2017.141628933581
   PubMed Web of Science ®Google Scholar
• DuarteA, TungL, ZhangW, HsuE, KuoY, SharmaG. Spirometry measurement of peak inspiratory flow identifies suboptimal use of dry powder inhalers in ambulatory patients with COPD. Chronic Obstr Pulm Dis. 2019;6(3):246–255. doi:10.15326/jcopdf.6.3.2018.016331189057
   PubMed Web of Science ®Google Scholar
• MahlerD, WatermanL, GiffordA. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26(3):174–179. doi:10.1089/jamp.2012.098723025451
   PubMed Web of Science ®Google Scholar
• MahlerD. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2017;14(7):1103–1107. doi:10.1513/AnnalsATS.201702-156PS28481631
   PubMed Web of Science ®Google Scholar
• IwanagaT, TohdaY, NakamuraS, SugaY. The Respimat® soft mist inhaler: implications of drug delivery characteristics for patients. Clin Drug Investig. 2019;39(11):1021–1030. doi:10.1007/s40261-019-00835-z
   PubMed Web of Science ®Google Scholar
• DalbyR, SpallekM, VoshaarT. A review of the development of respimat soft mist inhaler. Int J Pharm. 2004;283:1–9. doi:10.1016/j.ijpharm.2004.06.01815363496
   PubMed Web of Science ®Google Scholar
• NavaieM, DembekC, Cho-ReyesS, YehK, CelliR. Device use errors with soft mist inhalers: a global systematic literature review and meta-analysis. Chron Respir Dis. 2020;17:1479973119901234. doi:10.1177/147997311990123431984767
   PubMed Web of Science ®Google Scholar
• O’DriscollB, KayE, TaylorR, WeatherbyH, ChettyM, BernsteinA. A long-term prospective assessment of home nebulizer treatment. Respir Med. 1992;86(4):317–325. doi:10.1016/S0954-6111(06)80031-41448587
   PubMed Web of Science ®Google Scholar
• GardenhireD, BurnettD, StricklandS, MyersT. A guide to aerosol delivery devices for respiratory therapists; 2017 Available from: https://www.aarc.org/wp-content/uploads/2015/04/aerosol_guide_rt.pdf. Accessed 310, 2020.
   Google Scholar
• DolovichM, AhrensR, HessD, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335–371. doi:10.1378/chest.127.1.33515654001
   PubMed Web of Science ®Google Scholar
• MahlerD, OharJ, BarnesC, MoranE, PendyalaS, CraterG. Nebulized versus dry powder long-acting muscarinic antagonist bronchodilators in patients with COPD and suboptimal peak inspiratory flow rate. Chronic Obstr Pulm Dis. 2019;6:4.
   Web of Science ®Google Scholar
• BowlesS, SketrisI, KephartG. Drug evaluation alliance of nova scotia. Use of wet nebulized inhaled respiratory medications under criteria-based reimbursement guidelines in a publicly funded seniors’ pharmacare program in Nova Scotia, Canada. Am J Geriatr Pharmacother. 2007;5(2):120–128. doi:10.1016/j.amjopharm.2007.05.00317719514
   PubMedGoogle Scholar
• LarsonT. Economic impact and chronic obstructive pulmonary disease outcomes of a comprehensive inhaler to nebulization therapy protocol implementation in a large multi-state healthcare system. Curr Med Res Opin. 2019;35(10):1805–1817. doi:10.1080/03007995.2019.162856231172836
   PubMed Web of Science ®Google Scholar
• MoriatesC, NoveleroM, QuinnK, KhannaR, MouradM. “Nebs no more after 24”: a pilot program to improve the use of appropriate respiratory therapies. JAMA Intern Med. 2013;173(17):1647–1648. doi:10.1001/jamainternmed.2013.900223877555
   PubMed Web of Science ®Google Scholar
• AriA. Jet, ultrasonic, and mesh nebulizers: an evaluation of nebulizers for better clinical outcomes. Eurasian J Pulmonol. 2014;16:1–7. doi:10.5152/ejp.2014.00087
   Google Scholar
• IbrahimM, VermaR, Garcia-ContrerasL. Inhalation drug delivery devices: technology update. Med Devices (Auckl). 2015;8:131–139. doi:10.2147/MDER.S4888825709510
   PubMedGoogle Scholar
• RauJ, AriA, RestrepoR. Performance comparison of nebulizer designs: constant-output, breath-enhanced, and dosimetric. Respir Care. 2004;49:174–179.14744267
   PubMedGoogle Scholar
• DhandR. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care. 2002;47(12):1406–1416.12467499
   PubMedGoogle Scholar
• SkariaS, SmaldoneG. Omron NE U22: comparison between vibrating mesh and jet nebulizer. J Aerosol Med Pulm Drug Deliv. 2010;23(3):173–180. doi:10.1089/jamp.2010.081720500093
   PubMed Web of Science ®Google Scholar
• BiddiscombeM, UsmaniO. Is there room for further innovation in inhaled therapy for airways disease? Breathe. 2018;14:216–224. doi:10.1183/20734735.02031830186519
   PubMed Web of Science ®Google Scholar
• KopsaftisZ, SulaimanN, MountainO, Carson-ChahhoudK, PhillipsP, SmithB. Short-acting bronchodilators for the management of acute exacerbations of chronic obstructive pulmonary disease in the hospital setting: systematic review. Syst Rev. 2018;7(1):213. doi:10.1186/s13643-018-0860-030497532
   PubMed Web of Science ®Google Scholar
• DattaD, VitaleA, LahiriB, ZuWallackR. An evaluation of nebulized levalbuterol in stable COPD. Chest. 2003;124(3):844–849. doi:10.1016/S0012-3692(15)37638-812970007
   PubMed Web of Science ®Google Scholar
• NairS, ThomasE, PearsonS, HenryM. A randomized controlled trial to assess the optimal dose and effect of nebulized albuterol in acute exacerbations of COPD. Chest. 2005;128(1):48–54. doi:10.1378/chest.128.1.4816002915
   PubMed Web of Science ®Google Scholar
• BorkowskiJ, CraderM. Nebulized albuterol versus levalbuterol in pediatric and adult patients: a review. Formulary. 2009;44:108–118.
   Google Scholar
• Ipratropium Bromide (ipratropium bromide solution) [prescribing information]. Bonita Springs, FL: Cobalt Laboratories Inc; 2007 Available from: https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=lf69f100f-c766-490f-9143-5e8e0c8cb7c9&type=pdf&name=lf69f100f-c766-490f-9143-5e8e0c8cb7c9. Accessed 310, 2020.
   Google Scholar
• DuoNeb® (Ipratropium Bromide 0.5 mg/Albuterol Sulfate 3.0 mg*) inhalation solution [prescribing information]. CA: Dey Pharma, L.P Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020950s037lbl.pdf. Accessed 310, 2020.
   Google Scholar
• BaumgartnerR, HananiaN, CalhounW, SahnS, SciarappaK, HanrahanJ. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007;29(2):261–278. doi:10.1016/j.clinthera.2007.02.00917472819
   PubMed Web of Science ®Google Scholar
• DonohueJ, HananiaN, MakeB, et al. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014;146(6):1531–1542. doi:10.1378/chest.14-011725451347
   PubMed Web of Science ®Google Scholar
• GrossN, NelsonH, LapidusR, et al. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir Med. 2008;102(2):189–197. doi:10.1016/j.rmed.2007.10.00718363201
   PubMed Web of Science ®Google Scholar
• ZanenP, GoL, LammersJ. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax. 1996;51(10):977–980. doi:10.1136/thx.51.10.9778977595
   PubMed Web of Science ®Google Scholar
• KerwinE, DonohueJ, GoodinT, TosielloR, WheelerA, FergusonG. Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. Respir Med. 2017;132:238–250. doi:10.1016/j.rmed.2017.07.01128838685
   PubMed Web of Science ®Google Scholar
• FergusonG, GoodinT, TosielloR, WheelerA, KerwinE. Long-term safety of glycopyrrolate/eFlow® CS in moderate-to-very-severe COPD: results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study. Respir Med. 2017;132:251–260. doi:10.1016/j.rmed.2017.08.02028919143
   PubMed Web of Science ®Google Scholar
• FergusonG, FeldmanG, PudiK, et al. Improvements in lung function with nebulized revefenacin in the treatment of patients with moderate to very severe COPD: results from two replicate phase III clinical trials. Chronic Obstr Pulm Dis. 2019;6(2):154–165. doi:10.15326/jcopdf.6.2.2018.015230974049
   PubMed Web of Science ®Google Scholar
• DonohueJ, KerwinE, SethiS, et al. Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe chronic obstructive pulmonary disease (COPD). Respir Res. 2019;20(1):241. doi:10.1186/s12931-019-1187-731666076
   PubMed Web of Science ®Google Scholar
• DonohueJ, KerwinE, SethiS, et al. Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. Respir Med. 2019;153:38–43. doi:10.1016/j.rmed.2019.05.01031150963
   PubMed Web of Science ®Google Scholar
• SilerTM, MoranEJ, BarnesCN, CraterGD. Safety and efficacy of revefenacin and formoterol in sequence and combination via a standard jet nebulizer in patients with chronic obstructive pulmonary disease: a phase 3b, randomized, 42-day study. Chronic Obstr Pulm Dis. 2020;7(2):99–106. doi:10.15326/jcopdf.7.2.2019.015432324981
   PubMed Web of Science ®Google Scholar
• DonohueJ, FeldmanG, SethiS, et al. Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: evaluation in phase 3 clinical trials. Pulm Pharmacol Ther. 2019;57:101808. doi:10.1016/j.pupt.2019.10180831152911
   PubMed Web of Science ®Google Scholar
• LipsonD, BarnhartF, BrealeyN, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa171390129668352
   PubMed Web of Science ®Google Scholar
• PleasantsR, WangT, XuX, et al. Nebulized corticosteroids in the treatment of COPD exacerbations: systematic review, meta-analysis, and clinical perspective. Respir Care. 2018;63(10):1302–1310. doi:10.4187/respcare.0638430237276
   PubMed Web of Science ®Google Scholar
• MatkovicZ, MiravitllesM. Chronic bronchial infection in COPD. Is there an infective phenotype? Respir Med. 2013;107(1):10–22. doi:10.1016/j.rmed.2012.10.02423218452
   PubMed Web of Science ®Google Scholar
• MiravitllesM, AnzuetoA. Chronic respiratory infection in patients with chronic obstructive pulmonary disease: what is the role of antibiotics? Int J Mol Sci. 2017;18:7. doi:10.3390/ijms18071344
   Web of Science ®Google Scholar
• AlbertR, ConnettJ, BaileyW, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698. doi:10.1056/NEJMoa110462321864166
   PubMed Web of Science ®Google Scholar
• CuiY, LuoL, LiC, ChenP, ChenY. Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:3813–3829. doi:10.2147/COPD.S18124630538443
   PubMed Web of Science ®Google Scholar
• HerathS, NormansellR, MaiseyS, PooleP. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018;10:CD009764.30376188
   PubMed Web of Science ®Google Scholar
• Bruguera-AvilaN, MarinA, Garcia-OliveI, et al. Effectiveness of treatment with nebulized colistin in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2909–2915. doi:10.2147/COPD.S13842829042767
   PubMed Web of Science ®Google Scholar
• Dal NegroR, MichelettoC, TognellaS, ViscontiM, TuratiC. Tobramycin nebulizer solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation. Adv Ther. 2008;25(10):1019–1030. doi:10.1007/s12325-008-0105-218821068
   PubMed Web of Science ®Google Scholar
• SethiS, RennardS, MiravitllesM, et al. A Phase 2 study to evaluate the safety, tolerability and efficacy of levofloxacin inhalation solution (MP-376) administered for 5 days every 28 days to prevent acute exacerbations in high risk COPD patients. Am J Respir Crit Care Med. 2012;185:A3057.
   Google Scholar
• SoltaninejadF, KheiriS, HabibianR, AmraA, Asgari-SavadjaniS. Evaluation effects of nebulized gentamicin in exacerbation of chronic obstructive lung disease. J Res Med Sci. 2016;21:56. doi:10.4103/1735-1995.18727827904601
   PubMed Web of Science ®Google Scholar
• SinghD, Abbott-BannerK, NewmanK. The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients. Eur Respir J. 2016;48:OA1970.
   Web of Science ®Google Scholar
• NewmanK, SinghD. RPL554, a first-in-class dual PDE3/4 inhibitor, causes rapid additional bronchodilation when dosed with tiotropium in COPD patients. Am J Respir Crit Care Med. 2018;197:A4227.
   Web of Science ®Google Scholar
• MaurerB, SinghD, MartinezF, NewmanK. RPL554, a first-in-class dual PDE3/4 inhibitor, causes significant bronchodilation and symptom relief; a Phase 2b COPD study. Eur Respir J. 2018;52:OA1940. doi:10.1183/13993003.01675-2018
   Web of Science ®Google Scholar
• CazzolaM, CalzettaL, RoglianiP, MateraM. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert Opin Investig Drugs. 2019;28(10):827–833. doi:10.1080/13543784.2019.1661990
   PubMed Web of Science ®Google Scholar
• DhandR, MahlerD, CarlinB, et al. Results of a patient survey regarding COPD knowledge, treatment experiences, and practices with inhalation devices. Respir Care. 2018;63(7):833–839. doi:10.4187/respcare.0571529559537
   PubMed Web of Science ®Google Scholar
• MahlerD. Peak inspiratory flow rate: an emerging biomarker in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2019;199(12):1577–1579. doi:10.1164/rccm.201901-0005LE30892057
   PubMed Web of Science ®Google Scholar
• JanssensW, VandenBrandeP, HardemanE, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31:78–83. doi:10.1183/09031936.0002480717898020
   PubMed Web of Science ®Google Scholar
• LohC, PetersS, LovingsT, OharJ. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. Ann Am Thorac Soc. 2017;14(8):1305–1311. doi:10.1513/AnnalsATS.201611-903OC28406710
   PubMed Web of Science ®Google Scholar
• SharmaG, MahlerD, MayorgaV, DeeringK, HarshawO, GanapathyV. Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. Chronic Obstr Pulm Dis. 2017;4(3):217–224. doi:10.15326/jcopdf.4.3.2017.018328848933
   PubMed Web of Science ®Google Scholar
• MahlerD, WatermanL, WardJ, GiffordA. Comparison of dry powder versus nebulized β-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. J Aerosol Med Pulm Drug Deliv. 2014;27(2):103–109. doi:10.1089/jamp.2013.103823745526
   PubMed Web of Science ®Google Scholar
• BarronsR, PegramA, BorriesA. Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2011;68(13):1221–1232. doi:10.2146/ajhp10045221690428
   PubMed Web of Science ®Google Scholar
• MazyckA, SzymborskiS, NhanE, ReillyJ. Chemical and physical compatibility of revefenacin inhalation solution mixed with either albuterol sulfate, arformoterol tartrate, or budesonide. Am Soc Health System Pharmacists. 2019.
   Google Scholar
• PARI. Available from: https://pariorder.com. Accessed 76, 2020.
   Google Scholar
• Philips. SideStream Plus: Reusable nebulizer. Available from: https://www.usa.philips.com/healthcare/product/HC0077830/sidestream-plus-reusable-nebulizer. Accessed 76, 2020.
   Google Scholar
• Monaghan. Aeroeclipse® XL ban with Ombra® Compressor. Available from: https://www.monaghanmed.com/Aeroeclipse-XL-Ban-with-Ombra-Compressor/#1540799872824-7b01c579-2e33628f-29b55344-99b1. Accessed 76, 2020.
   Google Scholar
• Omron. Portable MicroAir® Nebulizer. Available from: https://omronhealthcare.com/products/microair-nebulizer-neu22v. Accessed 76, 2020.
   Google Scholar
• Akita® Jet. Available from: http://www.akita-jet.com. Accessed 76, 2020.
   Google Scholar